The clinical efficacy of pemirolast potassium for perennial nasal allergy

with special reference to its efficacy for nasal congestion

Abstract

The clinical efficacy of an oral anti-allergic drug, pemirolast potassium (Alegysal®), was evaluated in 97 patients with perennial allergic rhinitis by assessing the efficacy mainly for nasal congestion based on the nasal findings and the nasal air flow. The final global improvement rating was either “markedly improved” or “moderately improved” in 44.7% of the patients in week 4 of treatment and in 64.7% of the patients in or after week 5 of treatment. The overall safety rating was “adverse reactions occurred but the treatment was continued” in 3 patients. The utility rating was “very useful” or “moderately useful” in 48.9% of the patients in week 4 of treatment and 66.7% in or after week 5 of treatment. The nasal air peak flow value was determined using a simple air flow meter improved significantly after treatment, while that determined by the anterior (ANT) method only showed a slight tendency to improve after treatment. These findings thus suggested that Pemirolast potassium is useful for the treatment of perennial nasal allergy and especially improves the symptoms of nasal congestion by reducing the nasal air flow resistance.